The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering and subsequent merger with AbbVie Inc. [1] Group 1: Class Action Details - The class action lawsuit is on behalf of individuals or entities that sold or disposed of Cerevel's common stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [3] - The deadline for shareholders to register for the class action is June 3, 2025, and there is no cost to participate [5] Group 2: Allegations Against Cerevel - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price [4] - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [4] Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [6]